Not All Drug Abuse Is From Health Providers and Oxycodone – Pain Medicine News

family:arial,sans-serif”>Not All Drug Abuse Is From Health Providers and Oxycodone
Pain Medicine News
Over the last few months, there has been an explosion of interest in the legislature to rein in oxycodone and to limit its use for pain management. Health care providers are painted as the major culprits who are causing an explosion of drug abuse, as

See the article here:
(more…)

FDA approves oxycodone hydrochloride and naltrexone hydrochloride ER capsules CII with…

FDA has approved oxycodone hydrochloride and naltrexone hydrochloride (Troxyca ER—Pfizer) extended-release capsules, for oral use, CII for the management of pain severe enough to require daily, long-term opioid treatment. The drug is the only oxycodone with oral abuse-deterrent features described in the labeling.

FDA has approved oxycodone hydrochloride and naltrexone hydrochloride (Troxyca ER—Pfizer) extended-release capsules, for oral use, CII for the (more…)

FDA Approves Abuse-Deterrent, Extended-Release Oxycodone/Naltrexone (Troxyca ER) for Pain…

The FDA has given the nod to Troxyca ER (oxycodone hydrochloride and naltrexone hydrochloride, Pfizer) extended-release capsules for oral use (CII) for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

Troxyca ER has properties that are expected to reduce abuse when crushed and administered by the oral and intranasal (more…)